MARKET

ERAS

ERAS

Erasca, Inc.
NASDAQ
14.25
-0.27
-1.86%
After Hours: 14.31 +0.06 +0.42% 19:37 09/25 EDT
OPEN
14.62
PREV CLOSE
14.52
HIGH
14.89
LOW
14.23
VOLUME
3.22M
TURNOVER
--
52 WEEK HIGH
24.28
52 WEEK LOW
1.750
MARKET CAP
4.98B
P/E (TTM)
-14.9246
1D
5D
1M
3M
1Y
5Y
1D
Notable Friday Option Activity: APP, ERAS, CRDO
NASDAQ · 1d ago
Did Fiduciary Duty Probes Just Shift Erasca Stock's Investment Narrative?
Simply Wall St · 3d ago
Weekly Report: what happened at ERAS last week (0914-0918)?
Weekly Report · 6d ago
10 mid-cap healthcare stocks with the strongest momentum grades
Seeking Alpha · 09/17 14:10
These mid-cap stocks have A+ momentum grades and over 100% YTD growth
Seeking Alpha · 09/17 13:45
S&P 500 Futures Climb In Premarket Trading; Generac Holdings, UDR Lead
Dow Jones · 09/17 11:30
Erasca (ERAS) Dropped, So What Is Driving Attention Now?
Simply Wall St · 09/16 22:21
Erasca’s ERAS-601 Trial Completion: What Early Cancer Data Could Mean for Investors
TipRanks · 09/16 16:30
More
About ERAS
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.

Webull offers Erasca Inc stock information, including NASDAQ: ERAS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ERAS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ERAS stock methods without spending real money on the virtual paper trading platform.